COMPASS Pathways appoints Daphne Karydas to Board of Directors

COMPASS Pathways plc

Appointment effective September 18, 2023; Karydas is President/CFO of Flare Therapeutics.
Received initial option for 52,000 ordinary shares (or ADSs) vesting over three years.
Annual cash retainers: $40,000 as director, $8,000 as audit/risk committee member.
Serves as Class III director; brings over 20 years biopharma financial and strategy experience.
No family relationships with directors/officers; no material transactions disclosed.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daphne Karydas

Director

CMPS · COMPASS Pathways plc

Effective: 2023-09-18
Filed: September 18, 2023, 7:59 PM ET

On September 13, 2023, the board of directors (the “Board”) of COMPASS Pathways plc (the “Company”), upon the recommendation of its nominating and corporate governance committee, appointed Daphne Karydas to join the Board, effective September 1 8, 2023, and designated her as a Class III director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daphne Karydas was appointed as Director at COMPASS Pathways plc.

Action: appointed
Role: Director

Exact text from the filing

On September 13, 2023, the board of directors (the “Board”) of COMPASS Pathways plc (the “Company”), upon the recommendation of its nominating and corporate governance committee, appointed Daphne Karydas to join the Board, effective September 1 8, 2023, and designated her as a Class III director.

View on SEC.gov

COMPASS Pathways plc filing history →

Source: SEC EDGAR

accession 0001816590-23-000123

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.